ProQR Therapeutics Ownership
| PRQR Stock | USD 3.54 0.08 2.21% |
Shares in Circulation | First Issued 2013-09-30 | Previous Quarter 81.7 M | Current Value 81.7 M | Avarage Shares Outstanding 44.9 M | Quarterly Volatility 23.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ProQR |
ProQR Stock Ownership Analysis
About 14.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.31. ProQR Therapeutics had not issued any dividends in recent years. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Proqr Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about ProQR Therapeutics BV contact Daniel Boer at 31 88 166 7000 or learn more at https://www.proqr.com.Besides selling stocks to institutional investors, ProQR Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ProQR Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ProQR Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ProQR Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 14.0% of ProQR Therapeutics BV are currently held by insiders. Unlike ProQR Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ProQR Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ProQR Therapeutics' insider trades
ProQR Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProQR Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProQR Therapeutics BV backward and forwards among themselves. ProQR Therapeutics' institutional investor refers to the entity that pools money to purchase ProQR Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 155.9 K | Franklin Street Advisors Inc. | 2024-09-30 | 150 K | Millennium Management Llc | 2024-06-30 | 148.4 K | Two Sigma Advisers, Llc | 2024-06-30 | 131.5 K | Boothbay Fund Management, Llc | 2024-09-30 | 106.7 K | Susquehanna International Group, Llp | 2024-06-30 | 96.1 K | Citadel Advisors Llc | 2024-09-30 | 87 K | Squarepoint Ops Llc | 2024-06-30 | 84.7 K | Bank Of America Corp | 2024-06-30 | 73.2 K | Privium Fund Management B.v. | 2024-09-30 | 5.6 M | Adage Capital Partners Gp Llc | 2024-06-30 | 3.6 M |
ProQR Therapeutics Outstanding Bonds
ProQR Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProQR Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProQR bonds can be classified according to their maturity, which is the date when ProQR Therapeutics BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
ProQR Therapeutics Corporate Filings
6K | 7th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of October 2024 Other Reports | ViewVerify | |
| 30th of September 2024 Other Reports | ViewVerify | |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ProQR Stock
| 0.84 | MTEM | Molecular Templates | PairCorr |
| 0.83 | ME | 23Andme Holding | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | TPST | Tempest Therapeutics | PairCorr |
| 0.78 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.